Data Article

Data on the relationship of signal-to-cutoff ratio of two HIV antigen/antibody combination assays to subsequent confirmation of HIV-1 infection in a low-prevalence population

Christina K. Hodgson, Matthew D. Krasowski*, Bradley A. Ford

Department of Pathology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA

ARTICLE INFO

Article history:
Received 31 March 2020
Revised 6 May 2020
Accepted 7 May 2020
Available online 16 May 2020

Keywords:
False positive reaction
HIV-1
HIV-2
immunoassay
polymerase chain reaction
viral load

ABSTRACT

HIV-1/2 antigen/antibody (Ag/Ab) immunoassays that detect HIV-1 and HIV-2 antibodies and HIV-1 p24 antigen are commonly used in the diagnosis of HIV-1/HIV-2 infections in human plasma/serum. Samples from patients with positive screening results require confirmation by antibody differentiation and/or HIV PCR assays. HIV screening assays are commonly reported as positive or negative based on a signal-to-cutoff (S/CO) threshold. For some HIV screening assays, the strength of the S/CO value correlates with likelihood that confirmatory testing will be positive. The data in this article provide results from two HIV Ag/Ab combination assays (Abbott Architect HIV Ag/Ab Combo Assay, a 4th generation combination assay; Bio-Rad Bioplex 2200 HIV Ag-Ab Assay, a 5th generation assay). The data include 23,331 HIV screening results, S/CO ratios, antibody differentiation or Western blot results (for samples with positive HIV screens), HIV-1 PCR results (if performed), patient location at time of testing, age, and sex. Distribution of S/CO ratios for the Bio-Rad HIV screening assay data and the distribution of

* Corresponding author.
E-mail address: matthew-krasowski@uiowa.edu (M.D. Krasowski).

https://doi.org/10.1016/j.dib.2020.105707
2352-3409/© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license. (http://creativecommons.org/licenses/by/4.0/)
S/CO values for samples with positive screening results were analyzed.

© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license. (http://creativecommons.org/licenses/by/4.0/)

### Specifications Table

| Subject                      | Medicine and Dentistry |
|------------------------------|------------------------|
| Specific subject area        | Pathology and Medical Technology |
| Type of data                 | Tables                 |
|                              | Figures                |
|                              | Supplemental files     |
| How data were acquired       | Retrospective chart and data review from laboratory analysis performed at an academic medical center central clinical laboratory were obtained via tools within the electronic medical record. |
| Data format                  | Raw and Analyzed       |
| Parameters for data were collected | Retrospective data on all HIV screening and confirmatory tests was obtained from the electronic medical record (Epic, Inc.) covering the time period from January 1, 2014 through May 24, 2017. Detailed chart review was performed for all cases with positive HIV screening results except for testing for blood borne pathogen (BBP) exposures that were restricted from chart review. The project had approval from the University of Iowa Institutional Review Board. |
| Description of data collection | There were a total of 23,331 HIV screening tests performed on 19,177 (Architect 9,302, Bioplex 9,875) unique patients for clinical purposes during the retrospective analysis period. The study was a retrospective study approved by the University of Iowa Institutional Review Board (protocol # 201705802). The data collection also contains confirmatory HIV testing for positive screens. |
| Data source location         | Iowa City, Iowa, United States of America |
| Data accessibility           | Raw data are available in this article as 2 Supplementary files. Five tables and two figures are included within the paper. |

### Value of the Data

- The data provided are of value as HIV screening is widely performed in clinical, research, and public health settings.
- Clinicians, other researchers, or personnel in clinical laboratories might find this data useful as a reference for comparison.
- Our data set would serve as a starting point for researchers interested in future investigations investigating HIV screening false positives.
- The data are of value as there is very limited published data involving the relationship of signal/cutoff ratio and confirmation in 5th generation HIV screening tests.
- The data provide information for 23,331 HIV screening tests in 19,177 unique patients.

### 1. Data

In this retrospective analysis study, we compiled detailed data on 23,331 samples originating from 19,177 unique patients that had HIV screening testing performed at an academic medical center central clinical laboratory. There is a growing literature on the association of HIV screening assay signal-to-cutoff (S/CO) value with likelihood of subsequent confirmation by confirmatory testing such as Western blot, antibody differentiation assays, and HIV RNA PCR assay [1–6]. There were a total of 2,657 (Architect 2,002; 655 Bioplex) tests ordered as part of workup for BBP exposure to employees or students. For the purposes of the present study, a
true (confirmed) positive was determined by a positive result by Western blot, Bio-Rad Multipot, or Bio-Rad Geenius (note only Multipot and Geenius assays can differentiate between HIV-1 and HIV-2 Ab) and/or HIV RNA PCR. A non-true positive screen was defined as a reactive HIV screen without subsequent confirmation/diagnosis of HIV infection. To best ascertain HIV status, we performed extensive chart review in addition to analyzing the results of HIV discriminatory and RNA PCR testing.

Table 1 shows demographics of the population being tested, both overall and for those with positive screening tests. Table 2 shows overall performance characteristics of the two HIV screening assays. Table 3 shows the S/CO quantitative values associated with reactive HIV screens. Table 4 summarizes the discrete components for reactive HIV screens for the 5th generation Bioplex assay. Table 5 summarizes the performance of the two HIV screening tests using selected S/CO ratio thresholds. Fig. 1 displays the distribution of S/CO ratios for positive HIV screens for

| Table 1 | Demographics of HIV testing |
|---------|-----------------------------|
| **HIV screening** | **Architect** n = 11987 | **Bioplex** n = 11344 |
| **Location** | | |
| Inpatient | 1517 (12.7%) | 1259 (11.1%) |
| Outpatient | 10218 (85.2%) | 9790 (86.3%) |
| Emergency department | 252 (2.1%) | 295 (2.6%) |
| **Highest ordering specialty** | | |
| Obstetrics-gynecology | 2567 (21.4%) | 3555 (31.3%) |
| Family medicine | 1352 (11.3%) | 1372 (12.1%) |
| Transplant services | 867 (7.2%) | 772 (6.8%) |
| Internal medicine | 539 (4.5%) | 558 (4.9%) |
| **Confirmed positive screen** | | |
| Mean age (yrs) | 46 ± 11 | 41 ± 13 |
| Median age (yrs) | 46 | 40 |
| Male: female | 3:1 | 3:1 |
| **Non-true positive screen (initial screen positive, not confirmed)** | | |
| Mean age (yrs) | 40 ± 15 | 39 ± 14 |
| Median age (yrs) | 33 | 34 |
| Male: female | 0.6 | 0.8:1 |

| Table 2 | Performance of Architect and Bioplex HIV Ag/Ab assays |
|---------|-----------------------------|
| **HIV screening** | **Architect** n = 11987 | **Bioplex** n = 11344 | **Total** n = 23331 |
| Reactive screens | 52 | 58 | 110 |
| Nonreactive screens | 11935 | 11286 | 23221 |
| **HIV confirmation** | | | |
| Confirmed positives | 22 | 27 | 49 |
| Positive Western Blot | 7 | N/A | 7 |
| HIV-1 by Multipot | 14 | 18 | 32 |
| HIV-2 by Multipot | 1 | 0 | 1 |
| HIV-1 by Geenius | N/A | 9 | 9 |
| Non-true positives (confirmation negative) | 26 | 31 | 57 |
| Confirmatory test cancelledb | 4 | 0 | 4† |
| **Specificity** (95% CI) | 99.8% (99.7 - 99.9%) | 99.7% (99.6 - 99.8%) | 99.8% (99.7 - 99.8%) |
| **Positive Predictive Value** (95% CI) | 45.8% (36.6 - 55.4%) | 46.6% (38 - 55.3%) | 46.2% (39.9 - 52.7%) |

*a HIV-2 RNA was detected (but below the limited of quantification, <10 copies/mL) by subsequent HIV-2 PCR performed at the University of Washington (Seattle, WA) and New York State Department of Health Wadsworth Center (Albany, NY). This sample was also screen positive on the Bioplex assay when tested as part of validation studies.

b Confirmatory testing was cancelled in 4 cases for the Abbott Architect testing due to previously established HIV-1 diagnosis.
Table 3
S/CO Ratio Quantitative Values for Reactive Screens

| Architect HIV Ag/Ab Combo Assaya | Negative confirmation | Positive confirmation |
|----------------------------------|----------------------|----------------------|
| S/CO ratio                       | n = 11               | n = 12               |
| Median                           | 2                    | 826                  |
| Minimum                          | 1                    | 199                  |
| Maximum                          | 39                   | 1094                 |

| Bioplex HIV Ag/Ab Combo Assayb  | Negative confirmation | Positive confirmation |
|---------------------------------|----------------------|----------------------|
| S/CO ratio                      | n = 31               | n = 27               |
| Median                           | 3                    | >200                 |
| Minimum                          | 1                    | 131                  |
| Maximum                          | 45                   | >200 (n = 19)        |

a S/CO ratios were only available for 23 of 52 Architect positive screens. A single patient with a reactive Architect result had confirmed HIV-2 infection. Initial HIV testing was performed in this patient as part of routine screening for solid organ transplant evaluation. The quantitative S/CO ratio on the Architect assay was 237.48. The sample was later tested as part of validation studies for the Bioplex assay and had an S/CO ratio of > 200 for HIV-2 Ab (<1 for the two HIV-1 discrete components). HIV-2 antibodies were detected by Multispot confirmation. HIV-2 RNA was detected although below the assay’s limit of quantitation (<10 copies/mL) by real-time PCR (University of Washington Medical Center, Seattle, WA). HIV-2 RNA remained detectable at 8 and 9 months by real-time PCR but was no longer detected at 19 months from initial screening.

b S/CO ratios had maximum upper limit of 200 for the Bioplex. All values above this were simply reported as > 200.

Table 4
Discrete component for reactive Bioplex screens

| Reactive component (S/CO ratio ≥ 1) | HIV-1 Ab | HIV-2 Ab | HIV-1 p24 Ag | HIV-1 Ab, HIV-2 Abα | HIV-2 Ab, HIV-1 p24 Agβ | HIV-1 Ab, HIV-2 Ab, HIV-1 p24 Agα |
|-------------------------------------|----------|----------|--------------|---------------------|------------------------|----------------------------------|
| Confirmed positive screens (n = 27) | 27       | 0        | 0            | 0                   | 0                      | 0                                |
| Non-true positive screens (n = 31)  | 22       | 1        | 0            | 2                   | 1                      | 5                                |

α These Bioplex patterns combined cross-reactivity for HIV-1 Ab and HIV-2 Ab and are designated in the assay package insert as “undifferentiated HIV”, a result pattern uncommonly associated with actual HIV infection.

Table 5
Performance with Selected S/CO Ratio Thresholds

| Abbott Architect HIV Ag/Ab Combo Assay | PPV (%) | Sensitivity (%) |
|----------------------------------------|---------|-----------------|
| S/CO ratioa                           |         |                 |
| > 200                                  | 100%    | 100%            |
| > 150                                  | 100%    | 100%            |
| > 100                                  | 100%    | 100%            |

| Bio-Rad Bioplex HIV Ag/Ab Combo Assay | PPV (%) | Sensitivity (%) |
|--------------------------------------|---------|-----------------|
| S/CO ratio                           |         |                 |
| > 200                                 | 100%    | 70.4%           |
| > 150                                 | 100%    | 88.9%           |
| > 100                                 | 100%    | 100%            |

a S/CO quantitative values were available for 23 of 52 reactive Architect screens and 58 of 58 reactive Bioplex screens.
Fig. 1. Distribution of S/CO ratios for Confirmed Positives and Non-True Positive Results. Note: 19 Bioplex specimens had S/CO ratios that exceeded 200 (plotted together at 200).

Fig. 2. Distribution of S/CO ratios of negative Bioplex screens.

the Abbott Architect and Bioplex assays, indicating no overlap between the S/CO ratios for non-true positives and confirmed positives for either assay. Fig. 2 is a histogram plot of the S/CO ratios of HIV screens that were negative (< 1.0) on the Bioplex assays. The raw data for the study are included in Supplementary file 1 (Abbott Architect assay) and Supplementary file 2 (Bioplex assay).

• Supplementary file 1: Data for 11,987 HIV screening tests on 9,302 unique patients using the Abbott Architect 4th generation HIV assay. All laboratory data involve analysis on serum/plasma. Specific data fields include: unique patient identification number (deidentified), location/unit at time of testing (emergency department, inpatient, or outpatient), age in years, birth sex, HIV screening result, S/CO ratio (if available), confirmation method
2. Experimental Design, Materials, and Methods

This was a retrospective study approved by the University of Iowa Institutional Review Board (protocol # 201705802). During the retrospective analysis period, initial HIV testing was performed using the Abbott Architect HIV Ag/Ab immunoassay (Abbott Laboratories, Architect Park, IL) January 1, 2014 to November 22, 2015, which then transitioned to the Bio-Rad Bioplex 2200 HIV Ag-Ab Assay (Bioplex Laboratories, Hercules, CA) November 23, 2015 to May 24, 2017. The Abbott Diagnostics Architect HIV Ag/Ab Combo Assay is a widely used chemiluminescent 4th generation assay that simultaneously detects HIV-1 p24 Ag, HIV-1 gp41 Ab, and HIV-2 gp36 Ab and outputs a single signal-to-cutoff (S/CO) ratio that translates into a reactive/nonreactive qualitative result [5,7-9]. An S/CO ratio of 1.0 or greater on the Architect assay is considered positive, with repeat testing to verify the result. The Bio-Rad Bioplex 2200 HIV Ag-Ab Assay is an automated, multiplex flow 5th generation HIV immunoassay that provides discrete S/CO ratio results from detection of HIV-1 p24 Ag, HIV-1 Ab (groups M and O), and HIV-2 Ab, with similar overall sensitivity and specificity to other combination HIV Ag-Ab assays [10,11]. An S/CO ratio of 1 or greater on any of the three components of the Bioplex assay is interpreted as a positive screen, with repeat testing for all Bioplex positive screens before proceeding to confirmatory testing [12].

Beginning March 2015, quantitative S/CO ratios were captured in the laboratory information system and were thus available for 23 of 52 reactive Architect screens and all Bioplex HIV screens. The S/CO ratio for the Bioplex assay was determined by the highest S/CO ratio of the three components (HIV-1 p24 Ag, HIV-1 Ab groups M and O, and HIV-2 Ab). Reflex discriminatory or antibody differentiation testing for reactive screens (S/CO ratios of 1.0 or greater) was performed using Western blot for HIV-1 referred to a commercial reference laboratory (ARUP Laboratories, Salt Lake City, UT) January 2014 to October 2014, Bio-Rad Multispot HIV-1/HIV-2 Antibody Differentiation (Bio-Rad Laboratories, Redmond, WA) October 2014 to December 2016, or Bio-Rad Geenius HIV-1/HIV-2 Antibody Differentiation (Bio-Rad Laboratories, Redmond, WA) December 2016 to May 2017. These discriminatory tests, if positive, can confirm HIV infection. Medical record review was performed for all cases with S/CO ratio ≥ 1, except for cases in which HIV testing was ordered on a source patient, exposed employee, or student as part of a blood-borne pathogen (BBP) exposure workup (e.g., needlestick or scalp injury). Due to restricted access, data for HIV screening in BBP exposures was limited to HIV screening and confirmation laboratory results.

Acknowledgments

None.

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.dib.2020.105707.

References

[1] E.H. Adhikari, D. Macias, D. Gaffney, S. White, V.L. Rogers, D.D. McIntire, S.W. Roberts, Diagnostic accuracy of fourth-generation ARCHITECT HIV Ag/Ab Combo assay and utility of signal-to-cutoff ratio to predict false-positive HIV tests in pregnancy, Am J Obstet Gynecol 219 (4) (2018) 408 e1–408 e9 https://doi.org/10.1016/j.ajog.2018.06.008.

[2] R. Alonso, F. Perez-Garcia, P. Gijon, A. Collazos, E. Bouza, Evaluation of the Architect HIV Ag/Ab Combo Assay in a low-prevalence setting: The role of samples with a low S/CO ratio, J Clin Virol 103 (2018) 43–47 https://doi.org/10.1016/j.jcv.2018.04.002.

[3] T.O. Jensen, P. Robertson, R. Whybin, I. Chambers, M. Lahra, W. Rawlinson, J.J. Post, A signal-to-cutoff ratio in the Abbott architect HIV Ag/Ab Combo assay that predicts subsequent confirmation of HIV-1 infection in a low-prevalence setting, J Clin Microbiol 53 (5) (2015) 1709–1711 https://doi.org/10.1128/JCM.03583-14.

[4] S. Kim, J.H. Lee, J.Y. Choi, J.M. Kim, H.S. Kim, False-positive rate of a "fourth-generation" HIV antigen/antibody combination assay in an area of low HIV prevalence, Clin Vaccine Immunol 17 (10) (2010) 1642–1644 https://doi.org/10.1128/CVI.00258-10.

[5] C.A. Brennan, J. Yamaguchi, A. Vallari, P. Swanston, J.R. Hackett Jr., ARCHITECT(R) HIV Ag/Ab Combo assay: correlation of HIV-1 p24 antigen sensitivity and RNA viral load using genetically diverse virus isolates, J Clin Virol 57 (2) (2013) 169–172 https://doi.org/10.1016/j.jcv.2013.01.017.

[6] J. Parker, A.F. Carrasco, J. Chen, BioRad BioPlex(R) HIV Ag-Ab assay: Incidence of false positivity in a low-prevalence population and its effects on the current HIV testing algorithm, J Clin Virol 116 (2019) 1–3 https://doi.org/10.1016/j.jcv.2019.04.002.

[7] A.L. Manlutac, J.S. Giesick, P.A. McVay, Identification of early HIV infections using the fourth generation Abbott ARCHITECT HIV Ag/Ab Combo chemiluminescent microparticle immunoassay (CIA) in San Diego County, J Clin Virol 58 Suppl 1 (2013) e44–e47 https://doi.org/10.1016/j.jcv.2013.08.031.

[8] A. Kfutwah, V. Lemee, H.V. Ngono, F. De Oliveira, R. Njouom, J.C. Plantier, Field evaluation of the Abbott ARCHITECT HIV Ag/Ab Combo immunoassay, J Clin Virol 58 Suppl 1 (2013) e70–e75 https://doi.org/10.1016/j.jcv.2013.08.015.

[9] P. Chavez, L. Wesolowski, P. Patel, K. Delaney, S.M. Owen, Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay, J Clin Virol 52 Suppl 1 (2011) S51–S55 https://doi.org/10.1016/j.jcv.2011.09.010.

[10] S.H. Eshleman, E. Piwowar-Manning, M.V. Sivay, B. Debevec, S. Veater, L. McKinstry, L.G. Bekker, S. Mannheimer, R.M. Grant, M.A. Chesney, T.J. Coates, B.A. Koblin, J.M. Fogel, Performance of the BioPlex 2200 HIV Ag-Ab assay for identifying acute HIV infection, J Clin Virol 99-100 (2018) 67–70 https://doi.org/10.1016/j.jcv.2018.01.003.

[11] M. Salmons, S. Delarue, C. Delaugerre, F. Simon, S. Maylin, Clinical evaluation of BioPlex 2200 HIV Ag-Ab, an automated screening method providing discrete detection of HIV-1 p24 antigen, HIV-1 antibody, and HIV-2 antibody, J Clin Microbiol 52 (1) (2014) 103–107 https://doi.org/10.1128/JCM.02460-13.

[12] , Bio-Rad Bioplex 2200 System HIV Ag-Ab [package insert], Bio-Rad Laboratories, Inc., Hercules, CA, 2015 94547 https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/UCM455847.pdf (Accessed date: 31 March 2020).